Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in parkinson's disease patients: A double-blind single-dose study
Twelve parkinsonian patients with severely fluctuating symptoms were given a single dose of apomorphine or Dispersible Madopar on 2 consecutive days, to confirm the latter drug's usefulness in 'off' period rescue. According to our results, apomorphine proved faster in reverting '...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
Lippincott Williams and Wilkins
1997
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 04796caa a22007577a 4500 | ||
|---|---|---|---|
| 001 | PAPER-20173 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205134.0 | ||
| 008 | 190411s1997 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0030946523 | |
| 024 | 7 | |2 cas |a apomorphine, 314-19-2, 58-00-4; benserazide plus levodopa, 37270-69-2; levodopa, 59-92-7 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a CLNED | ||
| 100 | 1 | |a Merello, M. | |
| 245 | 1 | 0 | |a Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in parkinson's disease patients: A double-blind single-dose study |
| 260 | |b Lippincott Williams and Wilkins |c 1997 | ||
| 270 | 1 | 0 | |m Merello, M.; Movement Disorders Section, Raul Carrea Neurological Res. Inst., Montaneses 2325, (1428) Buenos Aires, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Marsden, C.D., Parkes, J.D., "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy (1976) Lancet, 1, pp. 292-296 | ||
| 504 | |a Steiger, M.J., Stocchi, F., Bramante, L., Ruggieri, S., Quinn, N.P., The clinical efficacy of single morning dose of levodopa methyl ester: Dispersible Madopar and Sinernet plus in Parkinson's disease (1992) Clin Neuropharmacol, 15, pp. 501-504 | ||
| 504 | |a Steiger, M.J., Stocchi, F., Carta, A., Ruggieri, S., Agnoli, A., Quinn, N.P., Marsden, C.D., The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease (1991) Clin Neuropharmacol, 14, pp. 241-244 | ||
| 504 | |a Stibe, C.M.H., Kempster, P.A., Lees, A.J., Stern, G.M., Subcutaneous apomorphine in parkinsonian on-off oscillations (1988) Lancet, 1, pp. 403-406 | ||
| 504 | |a Cooper, D.R., Marrel, C., Testa, B., L-dopa methyl-ester: A candidate for chronic systemic delivery of L-dopa in Parkinson's disease (1984) Clin Neuropharmacol, 7, pp. 89-98 | ||
| 504 | |a Stibe, C.M.H., Lees, A.J., Stern, G.M., Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuation (1987) Lancet, 1, p. 871 | ||
| 504 | |a Le Witt, P.A., Ward, C.D., Larsen, T.A., Comparison of pergolide and bromocriptine therapy in parkinsonism (1983) Neurology, 33, pp. 1009-1014 | ||
| 504 | |a Hardie, R.J., Lee, A.J., Stern, G.M., On-off fluctuations in Parkinson's disease: A clinical and neuropharmacology studs (1984) Brain, 107, pp. 487-506 | ||
| 520 | 3 | |a Twelve parkinsonian patients with severely fluctuating symptoms were given a single dose of apomorphine or Dispersible Madopar on 2 consecutive days, to confirm the latter drug's usefulness in 'off' period rescue. According to our results, apomorphine proved faster in reverting 'off' periods and should still be regarded as the drug of choice for this treatment modality. |l eng | |
| 593 | |a Movement Disorders Section, Neurology Department, Raul Carrea Inst. for Neurol. Res., Buenos Aires, Argentina | ||
| 593 | |a Movement Disorders Section, Raul Carrea Inst. for Neurol. Res., Montañeses 2325, 1428 Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a 'ON-OFF' PERIODS |
| 690 | 1 | 0 | |a APOMORPHINE |
| 690 | 1 | 0 | |a DISPERSIBLE MADOPAR |
| 690 | 1 | 0 | |a MOTOR FLUCTUATION |
| 690 | 1 | 0 | |a PARKINSON'S DISEASE |
| 690 | 1 | 0 | |a APOMORPHINE |
| 690 | 1 | 0 | |a BENSERAZIDE PLUS LEVODOPA |
| 690 | 1 | 0 | |a BRITAJECT |
| 690 | 1 | 0 | |a LEVODOPA |
| 690 | 1 | 0 | |a UNCLASSIFIED DRUG |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a CLINICAL ARTICLE |
| 690 | 1 | 0 | |a CLINICAL TRIAL |
| 690 | 1 | 0 | |a CONTROLLED CLINICAL TRIAL |
| 690 | 1 | 0 | |a CONTROLLED STUDY |
| 690 | 1 | 0 | |a DOUBLE BLIND PROCEDURE |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MOTOR DYSFUNCTION |
| 690 | 1 | 0 | |a ON OFF PHENOMENON |
| 690 | 1 | 0 | |a PARKINSON DISEASE |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a SUBCUTANEOUS DRUG ADMINISTRATION |
| 653 | 0 | 0 | |a britaject; madopar |
| 700 | 1 | |a Pikielny, R. | |
| 700 | 1 | |a Cammarota, A. | |
| 700 | 1 | |a Leiguarda, R. | |
| 773 | 0 | |d Lippincott Williams and Wilkins, 1997 |g v. 20 |h pp. 165-167 |k n. 2 |p CLIN. NEUROPHARMACOL. |x 03625664 |t Clinical Neuropharmacology | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0030946523&doi=10.1097%2f00002826-199704000-00008&partnerID=40&md5=072052e6dac5565e200b121742873d73 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1097/00002826-199704000-00008 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03625664_v20_n2_p165_Merello |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03625664_v20_n2_p165_Merello |y Registro en la Biblioteca Digital |
| 961 | |a paper_03625664_v20_n2_p165_Merello |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 81126 | ||